Showing results (61-70 of 71) with videos related to
Sort By:
Pageof 8
ACS Omega|August 29, 2019
Establishing Drug Discovery and Identification of Hit Series for the Anti-apoptotic Proteins, Bcl-2 and Mcl-1James B Murray, James Davidson, Ijen Chen, et al.Journal of Medicinal Chemistry|July 25, 2019
Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular ActivityZoltan Szlávik, Levente Ondi, Márton Csékei, et al.Journal of Medicinal Chemistry|November 4, 2020
Discovery of S64315, a Potent and Selective Mcl-1 InhibitorZoltan Szlavik, Marton Csekei, Attila Paczal, et al.Journal of Medicinal Chemistry|October 13, 2017
Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1)Douglas S Williamson, Garrick P Smith, Pamela Acheson-Dossang, et al.Journal of Medicinal Chemistry|November 19, 2020
Fragment-Based Discovery of Novel Non-Hydroxamate LpxC Inhibitors with Antibacterial ActivityYousuke Yamada, Hajime Takashima, David Lee Walmsley, et al.Molecular Cancer Therapeutics|April 14, 2007
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analoguesSwee Y Sharp, Chrisostomos Prodromou, Kathy Boxall, et al.Journal of Medicinal Chemistry|June 12, 2026
Structure-Based Discovery of Potent BCL-XL Inhibitors through RescaffoldingMatyas Pal Timari, Attila Paczal, Andras Herner, et al.Journal of Medicinal Chemistry|July 21, 2009
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperonePaul A Brough, Xavier Barril, Jenifer Borgognoni, et al.Cancer Research|April 17, 2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasisSuzanne A Eccles, Andy Massey, Florence I Raynaud, et al.Journal of Medicinal Chemistry|November 21, 2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancerPaul A Brough, Wynne Aherne, Xavier Barril, et al.Pageof 8